Latest news about Natural Capsules
Natural Capsules
155.95
+2.41(+1.57%)
Company Performance:
View Company Insights1D+1.57%
1M-4.89%
6M-18.94%
1Y-33.94%
5Y-37.51%
More news about Natural Capsules
25Apr 26
Natural Capsules Limited Announces Resignation of Company Secretary Pranjal Deshmukh
Natural Capsules Limited announced the resignation of Company Secretary & Compliance Officer Ms. Pranjal Deshmukh, effective April 25, 2026. She cited better career opportunities as the reason for her departure, with no other material reasons mentioned. The company has complied with all regulatory requirements under SEBI (LODR) Regulations, 2015, informing both BSE and NSE about this key managerial personnel change.
25Apr 26
Natural Capsules Limited Publishes IEPF Campaign Advertisement for Shareholder Outreach
Natural Capsules Limited published newspaper advertisements for IEPF Authority's Second 100 Days Campaign 'Saksham Niveshak' on April 24, 2026, in Business Line and Sanjeevani newspapers. The campaign targets shareholders with unpaid/unclaimed dividends and encourages KYC updates. The company informed BSE and NSE about the publication following its earlier intimation dated April 23, 2026.
03Apr 26
Natural Capsules Limited Opens Special Window for Physical Share Transfer and Dematerialization
Natural Capsules Limited has opened a special 12-month window from February 05, 2026 to February 04, 2027 for physical share transfer and dematerialization following SEBI circular. The facility is available for eligible shareholders with transfer deeds executed before April 01, 2019 and original share certificates. Transferred shares will be issued in demat form with a one-year lock-in period, excluding disputed cases and IEPF-transferred shares.
30Mar 26
Natural Capsules Limited Shareholders Approve Enhancement of Investment Limits
Natural Capsules Limited successfully concluded its postal ballot process on March 27, 2026, with shareholders providing exceptional support (99.99% approval) for enhancing limits on investments, loans, guarantees, and securities under Section 186 of the Companies Act, 2013. The e-voting process saw participation from 47 voting members representing 50.99% of outstanding shares, with results declared on March 30, 2026, following proper regulatory compliance and scrutinizer oversight.
17Mar 26
Natural Capsules Limited Receives Credit Rating Reaffirmation from Infomerics for Rs. 59.15 Crore Facilities
Natural Capsules Limited received reaffirmed credit ratings from Infomerics Valuation and Rating Limited for banking facilities totaling Rs. 59.15 crore. The rating agency assigned IVR BB+/Stable for long-term facilities worth Rs. 56.35 crore and IVR A4+ for short-term facilities of Rs. 2.80 crore. The facilities are distributed across State Bank of India, HDFC Bank, Siemens Financial Services, and Indian Renewable Energy Development Agency, with ratings valid until March 11, 2027.
13Mar 26
Natural Biogenex Partners with Fermbox Bio for Rs. 60 Crore Manufacturing Deal
Natural Capsules Limited announced a strategic manufacturing partnership through its subsidiary Natural Biogenex Private Limited with Fermbox Bio Private Limited, involving up to Rs. 60.00 crores investment in advanced fermentation technology and equipment at the Tumkur facility. The collaboration aims to strengthen fermentation-based CDMO capabilities for pharmaceutical and biotechnology sectors, combining NBPL's manufacturing expertise with Fermbox's advanced technology to serve global biotech and biopharma clients.
15Feb 26
Natural Capsules Limited Reports Q3 FY25 Financial Results with Revenue of ₹122.98 Crore
Natural Capsules Limited reported Q3 FY25 standalone results with total income of ₹122.98 crore and net profit of ₹49.33 crore. Nine-month performance showed total income of ₹378.12 crore and net profit of ₹180.51 crore. The company maintains strong financial position with net worth of ₹281.59 crore and low debt-equity ratio of 0.07. Results were approved by the Board on February 13, 2026.
13Feb 26
Natural Capsules Q3FY26 Results Reflect Operational Headwinds Amid Regulatory Challenges
Natural Capsules Limited reported challenging Q3FY26 results with revenue declining 18% QoQ to ₹37.75 crore and EBITDA turning negative at ₹(2.33) crore. The performance was impacted by temporary shutdown of the Puducherry unit due to regulatory issues, which have since been resolved. Positive developments include easing of US trade tariffs on HPMC capsules and advanced discussions for fermentation block partnerships. Management expects meaningful improvement in Q4FY26 with both plants operational and improved market visibility.
30Jan 26
Natural Capsules Limited Resumes Pondicherry Operations After High Court Suspends Plant Closure Order
Natural Capsules Limited has resumed operations at its Pondicherry manufacturing plant after the Madras High Court suspended the Drug Controller's temporary closure order. The court order, received on January 29, 2026, addressed a regulatory violation involving material supply to a customer with expired drug license. The temporary closure had resulted in decreased sales of approximately Rs. 6 crores for the pharmaceutical manufacturer.
03Jan 26
Natural Capsules Subsidiary Cancels Rights Issue Due to Non-Subscription
Natural Capsules Limited announced that its material subsidiary Natural Biogenex Private Limited has decided not to proceed with the allotment of shares under the previously approved rights issue worth ₹1.11 crore due to non-subscription by the major shareholder. The company also disclosed the upcoming retirement of Chief Operating Officer Mr. MVN Kutty due to superannuation, effective September 30, 2025.
26Dec 25
Natural Capsules Limited Pondicherry Plant Temporarily Closed by Drug Controller
Natural Capsules Limited's Pondicherry manufacturing plant has been temporarily closed by the Department of Drug Controller on December 26, 2025, for allegedly supplying materials to a customer with an expired drug license. The company is taking corrective actions and will submit documents for revocation of the closure order, though the financial impact remains to be determined.
19Nov 25
Natural Capsules Reports Net Loss Amid US Tariff Challenges and API Scale-Up Issues
Natural Capsules Limited posted a net loss of Rs 6.99 crores in Q2 FY26 despite 1.33% revenue growth to Rs 45.80 crores. HPMC capsule exports were affected by US tariffs, while the API division faced scaling issues. Gelatin capsule production increased, but HPMC production decreased significantly. The company revised its annual revenue guidance from Rs 270-280 crores to Rs 225 crores. Strategic initiatives include engaging Chinese consultants, exploring contract manufacturing, and diversifying export markets. Management expects API production issues to resolve by Q4 FY26 and aims for cash break-even in the API division at Rs 100 crores revenue.
14Nov 25
Natural Capsules Reports Q2 FY26 Loss Amid US Tariff Impact and API Production Challenges
Natural Capsules Limited reported a net loss of ₹6.99 crores in Q2 FY26, up from ₹5.58 crores in the previous quarter. Revenue grew 1.33% QoQ to ₹45.80 crores, but EBITDA margins turned negative at -1.93%. The company's capsules business faced headwinds due to 88% tariffs on Indian exports to the US market. Their API manufacturing venture encountered technical difficulties in scaling up production. Despite challenges, the company remains optimistic about long-term prospects and plans to commission a new production line by the end of the current quarter.
13Nov 25
Natural Capsules Limited Reports Mixed Q2 Results, Declines Subsidiary Rights Issue
Natural Capsules Limited announced Q2 and H1 FY2025-26 results. Standalone performance showed resilience with Q2 revenue at Rs. 4,458.02 lakhs and net profit at Rs. 281.05 lakhs. H1 standalone revenue reached Rs. 8,882.31 lakhs with Rs. 533.35 lakhs net profit. Consolidated results revealed challenges with Q2 net loss of Rs. 677.85 lakhs and H1 net loss of Rs. 1,286.95 lakhs, mainly due to subsidiary Natural Biogenex's performance. The company decided against subscribing to Natural Biogenex's rights issue, citing ongoing project commitments. Segment-wise, Capsules generated Rs. 4,458.02 lakhs revenue with Rs. 514.96 lakhs profit, while API segment showed Rs. 122.24 lakhs revenue but higher profitability at Rs. 859.45 lakhs.
05Aug 25
Natural Capsules Limited Shareholders Approve Key Board Changes and Appointments at 32nd AGM
Natural Capsules' 32nd AGM saw shareholders approve several important resolutions. Mr. Tekkar Yashwanth Prabhu will continue as Non-Executive Independent Director beyond 75 years. Mr. Sathyanarayana Mundra was reappointed as Whole Time Director for three years. Mr. R. Parthasarathy was appointed as Secretarial Auditor for five years. Other approvals included adoption of financial statements, reappointment of Mr. Sushil Kumar Mundra, related party transactions, and commission for Non-Executive Directors. All resolutions passed with overwhelming majority.
04Aug 25
Natural Capsules Reports Mixed Q1 Results: Standalone Profit Amid Consolidated Loss
Natural Capsules reported mixed Q1 financial results. Standalone performance showed growth with Rs 44.24 crore revenue and Rs 2.52 crore net profit. Consolidated results reflected challenges, with Rs 45.20 crore revenue but Rs 5.58 crore net loss. The Capsules segment remained profitable, while the new API segment incurred significant losses. The subsidiary, Natural Biogenex Private Limited, started operations recently and is yet to reach full revenue potential.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,807.70
(+0.75%)
6,638.00
(-0.26%)
4,571.20
(-0.02%)
1,389.40
(+0.44%)
1,104.70
(-0.11%)
1,275.40
(-0.05%)
2,293.30
(+0.88%)
2,381.10
(+0.35%)
1,472.80
(+0.59%)
1,394.30
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
